blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2501407

EP2501407 - ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  15.05.2015
Database last updated on 18.11.2024
Most recent event   Tooltip15.05.2015Application deemed to be withdrawnpublished on 17.06.2015  [2015/25]
Applicant(s)For all designated states
Amgen Inc.
Patent Operations M/S 28-2-C
One Amgen Center Drive
Thousand Oaks, California 91320-1799 / US
[2012/39]
Inventor(s)01 / NGUYEN, Hung, Q.
2801 Avenida De Autlan
Camarillo, CA 93010 / US
02 / LIN, Fen-Fen
1245 Belleflower Road
Carlsbad, CA 92011 / US
03 / BI, Xiao-juan
5186 Via Capote
Newbury Park, CA 91320 / US
04 / MCBRIDE, Helen J.
4510 Santa Lucia Drive
Woodland Hills, CA 91364 / US
05 / HU, Shaw-Fen, Sylvia
986 Lynnmere Drive
Thousand Oaks, CA 91360 / US
 [2012/39]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstrasse 4
80802 München / DE
[N/P]
Former [2012/39]Grünecker, Kinkeldey, Stockmair & Schwanhäusser
Leopoldstrasse 4
80802 München / DE
Application number, filing date10788171.619.11.2010
WO2010US57496
Priority number, dateUS20090263176P20.11.2009         Original published format: US 263176 P
US20100406054P22.10.2010         Original published format: US 406054 P
[2012/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011063277
Date:26.05.2011
Language:EN
[2011/21]
Type: A1 Application with search report 
No.:EP2501407
Date:26.09.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 26.05.2011 takes the place of the publication of the European patent application.
[2012/39]
Search report(s)International search report - published on:EP26.05.2011
ClassificationIPC:A61K39/395, A61P37/06, C07K14/705, C07K16/28, C07K19/00
[2012/39]
CPC:
C07K16/28 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P1/16 (EP); A61P1/18 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P19/06 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/04 (EP);
A61P33/02 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P7/02 (EP); A61P7/04 (EP); A61P9/00 (EP);
A61P9/02 (EP); A61P9/10 (EP); C07K14/47 (EP,US);
A61K2039/505 (EP,US); C07K2317/21 (EP,US); C07K2317/76 (EP,US);
C07K2317/92 (EP,US); C07K2319/00 (EP,US); C07K2319/60 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/39]
Extension statesBA15.06.2012
ME15.06.2012
TitleGerman:ANTI-ORAI1-ANTIGENBINDENDE PROTEINE UND IHRE VERWENDUNG[2012/39]
English:ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF[2012/39]
French:PROTÉINES DE LIAISON À UN ANTIGÈNE ANTI-ORAI1 ET LEURS UTILISATIONS[2012/39]
Entry into regional phase15.06.2012National basic fee paid 
15.06.2012Designation fee(s) paid 
15.06.2012Examination fee paid 
Examination procedure15.06.2012Examination requested  [2012/39]
09.01.2013Amendment by applicant (claims and/or description)
28.03.2013Despatch of a communication from the examining division (Time limit: M04)
07.08.2013Reply to a communication from the examining division
30.10.2013Despatch of a communication from the examining division (Time limit: M02)
17.12.2013Reply to a communication from the examining division
19.02.2014Despatch of a communication from the examining division (Time limit: M04)
01.07.2014Reply to a communication from the examining division
03.09.2014Despatch of a communication from the examining division (Time limit: M04)
14.01.2015Application deemed to be withdrawn, date of legal effect  [2015/25]
06.02.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2015/25]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.03.2013
Fees paidRenewal fee
13.11.2012Renewal fee patent year 03
18.11.2013Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.11.201405   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2007121186  (QUEENS MEDICAL CT [US], et al);
Examination   - Jennifer H. Cox ET AL, "Antibody-Mediated Targeting of the Orai1 Calcium Channel Inhibits T Cell Function", PLoS ONE, (20131223), vol. 8, no. 12, doi:10.1371/journal.pone.0082944, ISSN 1932-6203, page e82944, XP055102143

DOI:   http://dx.doi.org/10.1371/journal.pone.0082944
    - U. Y. Schaff ET AL, "Orai1 regulates intracellular calcium, arrest, and shape polarization during neutrophil recruitment in shear flow", Blood, (20100121), vol. 115, no. 3, doi:10.1182/blood-2009-05-224659, ISSN 0006-4971, pages 657 - 666, XP055102147

DOI:   http://dx.doi.org/10.1182/blood-2009-05-224659
by applicantUS3773919
 US3941763
 US4179337
 US4301144
 USRE30985E
 US4495285
 US4496689
 US4560655
 US4609546
 WO8700195
 US4640835
 US4657866
 US4670417
 US4676980
 WO8705330
 WO8801649
 US4766106
 US4767704
 US4791192
 US4816567
 EP0315456
 US4892538
 WO9003430
 US4927762
 US4946778
 EP0404097
 WO9110741
 WO9117271
 WO9201047
 EP0481790
 US5122469
 WO9311161
 WO9312366
 US5229275
 WO9319172
 US5260203
 WO9325673
 US5283187
 WO9402602
 US5302697
 WO9413806
 WO9515388
 US5545403
 US5545807
 WO9627011
 WO9630498
 US5565332
 WO9632478
 US5567610
 WO9633735
 US5573905
 US5589369
 US5591669
 WO9734631
 WO9824893
 US5877293
 US5939598
 US5989830
 US6022952
 US6054287
 WO0024782
 US6171586
 US6331415
 US6335178
 US2002004215
 US2002199213
 US2003044772
 US2003092125
 WO03041600
 US2003104400
 US2003113316
 US2003118592
 US2003133939
 US2003190317
 US6696267
 WO2004078995
 US2005037421
 US2005107436
 US2005136049
 US2005148633
 US7029909
 US7064244
 US2007071764
 WO2007045463
 WO2007081804
 WO2007121186
 US2008039392
 WO2008039520
 WO2008063504
 US2008132513
 WO2008088422
 WO2008091425
 US2008179539
 US2008207641
 WO2008110348
 US2008293092
 WO2008148108
 US2008318207
 WO2009000099
 WO2009017819
 WO2009017818
 US2009048122
 WO2009035818
 EP2103311
 WO2009115609
 WO2010108153
 WO2007US22831
 US20090210594
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.